US interest in MS drug boosts GW

April 24, 2006

Stephen Foley, The Independent (UK)

US investors piled into GW Pharmaceuticals yesterday amid excitement over the prospects for an American launch of its revolutionary cannabis-based treatment for multiple sclerosis.

Health regulators have sent an uncompromising message that smoked cannabis will not be approved for use by MS sufferers, leaving the way open for GW's under-the-tongue spray version of the drug.



Be the first to Comment

Please check your e-mail for a link to activate your account.